Literature DB >> 15181355

Reliability and validity of the Melbourne Edge Test and High/Low Contrast Visual Acuity chart.

Sharon A Haymes1, Jason Chen.   

Abstract

PURPOSE: The purposes of the study were to investigate the test-retest reliability and the validity of new versions of the Melbourne Edge Test (MET) and the High/Low Contrast Visual Acuity (H/LCVA) chart and to investigate the agreement between the original and new versions.
METHODS: The MET original photographic version, MET new light box version, H/LCVA Chart original photographic version, H/LCVA Chart new printed version, and the Pelli-Robson chart were administered twice to one eye of 22 subjects with low vision and 20 soft contact lenses wearers.
RESULTS: For the low vision group, the test-retest 95% limits of agreement were +/- 5.2 dB for the MET new light box version and +/- 0.39 logarithm of the minimum angle of resolution (logMAR) for the LCVA component of the H/LCVA new printed version. For the soft contact lens group, the test-retest 95% limits of agreement were +/- 2.1 dB for the MET new light box version and +/- 0.26 logMAR for the LCVA component of the H/LCVA new printed version. Moderate to high correlations were obtained between contrast sensitivity tests, thus providing evidence of validity. Scores obtained for the new test versions were significantly higher than the original versions (p < 0.01).
CONCLUSIONS: Of all the tests administered, the MET original photographic version and the Pelli-Robson Chart had the highest test-retest reliability for the low vision group. For the soft contact lens group, the H/LCVA original version (low contrast letters, 18% Weber) and the Pelli-Robson Chart had the highest reliability.

Mesh:

Year:  2004        PMID: 15181355     DOI: 10.1097/01.opx.0000134904.21274.db

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  8 in total

1.  Neurocognitive and Muscular Capacities Are Associated with Frailty in Adults with Cirrhosis.

Authors:  Susan L Murphy; James K Richardson; Jennifer Blackwood; Beanna Martinez; Elliot B Tapper
Journal:  Dig Dis Sci       Date:  2020-01-25       Impact factor: 3.199

2.  Validation of Simplified Visual Acuity Testing Protocols in Amyotrophic Lateral Sclerosis.

Authors:  Lindsay C Boven; Qin Li Jiang; Heather E Moss
Journal:  Neuroophthalmology       Date:  2017-04-27

3.  Test-retest Repeatability of the Ohio Contrast Cards.

Authors:  Mawada Osman; Stevie M Njeru; Gregory R Hopkins; Angela M Brown
Journal:  Optom Vis Sci       Date:  2021-09-01       Impact factor: 2.106

4.  Dual-tasking impacts gait, cognitive performance, and gaze behavior during walking in a real-world environment in older adult fallers and non-fallers.

Authors:  Lisa A Zukowski; Jaclyn E Tennant; Gozde Iyigun; Carol A Giuliani; Prudence Plummer
Journal:  Exp Gerontol       Date:  2021-04-07       Impact factor: 4.253

5.  Prevalence, Circumstances, and Risk Factors of Falls Among Community Dwelling Members of University of the Third Age.

Authors:  Asmidawati Ashari; Tengku Aizan Hamid; Mohd Rizal Hussain; Rahimah Ibrahim; Keith D Hill
Journal:  Front Public Health       Date:  2021-11-24

6.  Co-morbidity of depression and anxiety in common age-related eye diseases: a population-based study of 662 adults.

Authors:  Ranmalee Eramudugolla; Joanne Wood; Kaarin J Anstey
Journal:  Front Aging Neurosci       Date:  2013-10-02       Impact factor: 5.750

7.  Effects of transcranial direct current stimulation on gait in people with Parkinson's disease: study protocol for a randomized, controlled clinical trial.

Authors:  Vida Alizad; Marcus Meinzer; Laurent Frossard; Remco Polman; Simon Smith; Graham Kerr
Journal:  Trials       Date:  2018-11-29       Impact factor: 2.279

8.  Effect of the environment on gait and gaze behavior in older adult fallers compared to older adult non-fallers.

Authors:  Lisa A Zukowski; Gözde Iyigün; Carol A Giuliani; Prudence Plummer
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.